Health Care • Medicinal Chemicals and Botanical Products
$1.17 ▲ +0.02
(+1.74%)
MKT CAP: $42.0M • VOL: 127.0K
52W L $1 52W H $3
BTMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $192.2M | $197.2M | $185.4M |
| YoY Revenue Growth % | -2.5% | +6.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $35.6M | $31.6M | $28.7M |
| Operating Margin % | 18.5% | 16.0% | 15.5% |
| Net Income (GAAP) | $27.0M | $3.2M | $3.3M |
| EBITDA (Normalized) | $39.6M | $36.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $35.2M | $45.2M | $26.9M |
| Capital Expenditures (CapEx) | $5.0M | $6.4M | — |
| Free Cash Flow (FCF) | $30.2M | $38.8M | $26.9M |
| FCF Margin % | 15.7% | 19.7% | 14.5% |
| Return on Invested Capital (ROIC %) | 95.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $24.1M | $39.3M | — |
| Total Debt (Short + Long Term) | $95.8M | $101.2M | — |
| Total Stockholders' Equity | -$58.5M | -$105.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BTMD.